SCHEMBL6729378

SCHEMBL6729378

CC(=O)OCCn1c(=O)c2cc(C(=O)O)sc2n(C)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
ADORA2B P29275 3/20 0.49
GAA P10253 2/20 0.40
POLB P06746 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PARG Q86W56 1/20 0.36
KDM4E B2RXH2 7/20 0.36
HPGD P15428 2/20 0.36
ABL1 P00519 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
RIN1 Q13671 1/20 0.36
MAPT P10636 3/20 0.35
KMT2A Q03164 3/20 0.33
SLC18A3 Q16572 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 2/20 0.33
USP2 O75604 1/20 0.33
IDO1 P14902 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6254710 0.85 ALDH1A1 (0.46) ALDH1A1ADORA2BGAAKDM4EHPGD
SCHEMBL7021108 0.83 ALDH1A1 (0.41) ALDH1A1ADORA2BKDM4EHPGDCYP1A2
SCHEMBL7035440 0.82 KDM4E (0.40) ALDH1A1ADORA2BKDM4EHPGDMAPT
SCHEMBL7105492 0.78 HDAC8 (0.47) ALDH1A1ADORA2BGAAPOLBNPSR1
SCHEMBL6462794 0.78 MMP13 (0.41) ALDH1A1ADORA2BKDM4EHPGDABL1
SCHEMBL7020488 0.78 TRPA1 (0.41) ALDH1A1PARGKDM4EHPGDABL1
SCHEMBL6254110 0.77 TRPA1 (0.48) ALDH1A1ADORA2BKDM4EHPGDCYP3A4
SCHEMBL7105942 0.76 ADORA2B (0.48) ALDH1A1ADORA2BGAAPOLBNPSR1
SCHEMBL6703224 0.72 PTGS1 (0.41)
SCHEMBL6472154 0.72 MEN1 (0.43) ALDH1A1KDM4EMAPTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US claimed
US-20040019053-A1 Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib ROARK WILLIAM HOWARD (US) 2004-01-29 US disclosed
US-20040019054-A1 Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib ROARK WILLIAM HOWARD (US) 2004-01-29 US disclosed
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors MMP13, MMP3, MMP25 ALDH1A1 812/4885ADORA2B 1759/4885GAA 3750/4885
US-20040019053-A1 Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib MMP13, MMP11, MMP10 ALDH1A1 1764/4885ADORA2B 2019/4885GAA 694/4885
US-20040019054-A1 Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib MMP13, MMP11, MMP10 ALDH1A1 878/4885ADORA2B 1282/4885GAA 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.